CareDx Inc (CDNA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CareDx Inc (CDNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3424
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used which helps clinicians to monitor and identify acute cellular rejection in heart transplant recipients. It develops products for transplant monitoring including AlloSure, a next-generation sequencing test to detect donor-derived cell-free DNA after transplantation. CareDx also develop and commercialize post-transplant surveillance solutions to improve recipient outcomes. It offers novel surveillance management solutions to transform long-term patient care in transplantation. CareDx is headquartered in Brisbane, California, the US.

CareDx Inc (CDNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CareDx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CareDx Inc, Medical Devices Deals, 2012 to YTD 2018 9
CareDx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CareDx Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CareDx Secures USD15 Million in Venture Funding 11
Partnerships 12
CareDx Enters into Co-Development Agreement with Horizon Discovery 12
Licensing Agreements 13
CareDx Amends Licensing Agreement with Stanford University 13
Equity Offering 14
CareDx Files Registration Statement to Raise Funds through Public Offering of Shares 14
Acquisition 15
CareDx Acquires Allenex for up to USD34.1 Million 15
Allenex to Acquire Remaining Stake in Olerup SSP, AbSorber, Olerup International and Olerup for USD2.4 Million 17
CareDx Completes Acquisition of ImmuMetrix 18
CareDx Inc – Key Competitors 19
CareDx Inc – Key Employees 20
CareDx Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 09, 2018: Caredx reports second quarter results 22
May 10, 2018: CareDx Reports First Quarter Results 24
Mar 22, 2018: CareDx Announces Fourth Quarter And FY2017 Financial Results 25
Jan 08, 2018: CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 27
Nov 09, 2017: CareDx Reports Third Quarter 2017 Financial Results 28
Aug 10, 2017: CareDx Reports Second Quarter 2017 Financial Results 29
Jun 09, 2017: CareDx Reports First Quarter 2017 Financial Results 30
May 22, 2017: CareDx Reports Preliminary First Quarter 2017 Financial Results 31
Apr 21, 2017: CareDx Reports Fourth Quarter and Full Year 2016 Financial Results 32
Mar 15, 2017: CareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results 33
Corporate Communications 35
Jun 28, 2018: Flatiron Health CMO/CSO Joins CareDx Board of Directors 35
Apr 21, 2017: CareDx Appoints Michael Bell as Chief Financial Officer 36
Other Significant Developments 37
Jun 19, 2018: CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
CareDx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CareDx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CareDx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
CareDx Inc, Medical Devices Deals, 2012 to YTD 2018 9
CareDx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CareDx Secures USD15 Million in Venture Funding 11
CareDx Enters into Co-Development Agreement with Horizon Discovery 12
CareDx Amends Licensing Agreement with Stanford University 13
CareDx Files Registration Statement to Raise Funds through Public Offering of Shares 14
CareDx Acquires Allenex for up to USD34.1 Million 15
Allenex to Acquire Remaining Stake in Olerup SSP, AbSorber, Olerup International and Olerup for USD2.4 Million 17
CareDx Completes Acquisition of ImmuMetrix 18
CareDx Inc, Key Competitors 19
CareDx Inc, Key Employees 20
CareDx Inc, Subsidiaries 21

List of Figures
CareDx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CareDx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CareDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CareDx Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[CareDx Inc (CDNA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TAP Biosystems Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a medical laboratory that provides laboratory and pharmaceutical equipment. The laboratory offers products such as single-use mini bioreactor systems and automated cell culture systems. It also provides labware, consu …
  • Micell Technologies Inc:企業の製品パイプライン分析2018
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company provides product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to opt …
  • Laboratory Corporation of America Holdings:企業のM&A・事業提携・投資動向
    Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Hitachi Zosen Corporation (7004)-エネルギー分野:企業M&A・提携分析
    Summary Hitachi Zosen Corporation (Hitachi Zosen) is an industrial and engineering company that manufactures heavy industrial machinery. It conducts design and construction of process equipment, environmental systems, industrial plants, infrastructure-related equipment, disaster prevention systems, …
  • Siemens Gamesa Renewable Energy S.A.:企業の戦略・SWOT・財務情報
    Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report Summary Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Nissan Motor Co Ltd (7201):企業の財務・戦略的SWOT分析
    Nissan Motor Co Ltd (7201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Crew Energy Inc (CR):石油・ガス:M&Aディール及び事業提携情報
    Summary Crew Energy Inc (Crew Energy) is an exploration and production company that offers our long-term production and development of crude oil and natural gas resources. The company offers exploration, development, strategic acquisitions, operations, management, and production programs. It operate …
  • Risk Strategies Company Inc:企業のM&A・事業提携・投資動向
    Risk Strategies Company Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Risk Strategies Company Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Schindler Holding Ltd.:企業の戦略・SWOT・財務情報
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Energate Inc:企業の戦略的SWOT分析
    Energate Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Apyx Medical Corp (BVX):企業の財務・戦略的SWOT分析
    Summary Apyx Medical Corp (Apyx Medical) formerly known as Bovie Medical Corp is a medical technology company. The company manufactures and develops cosmetic and surgical products. The company also develops J-Plasma, a helium-based plasma surgical product for cutting, coagulation and ablation of sof …
  • Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychia …
  • Relief Therapeutics Holding AG (RLF):企業の財務・戦略的SWOT分析
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 to treat pe …
  • Sunningdale Tech Ltd (BHQ):企業の財務・戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company that manufactures and markets tooling and plastic injection moulding components. The company's plastic solutions include product and mould designs, injection moulding, mould fabrication, complementary finishings, and precision assembly …
  • Deutsche Bahn AG:企業の戦略・SWOT・財務情報
    Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aohata Corporation:企業の戦略・SWOT・財務情報
    Aohata Corporation - Strategy, SWOT and Corporate Finance Report Summary Aohata Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Apexigen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company t hat focuses on discovery and development of antibody-based drugs for the treatment of cancer.The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell r …
  • CommScope Holding Company Inc:企業のM&A・事業提携・投資動向
    CommScope Holding Company Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CommScope Holding Company Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Cemex SAB de CV (CEMEXCPO):企業の財務・戦略的SWOT分析
    Cemex SAB de CV (CEMEXCPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Detour Gold Corp:企業の戦略・SWOT・財務分析
    Detour Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Detour Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆